February 21, 2018 / 1:23 PM / in 9 months

BRIEF-Abbvie Announces Positive Topline Results From Phase 3 Study Evaluating Investigational Elagolix In Women With Uterine Fibroids

Feb 21 (Reuters) - Abbvie Inc:

* ABBVIE ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 3 STUDY EVALUATING INVESTIGATIONAL ELAGOLIX IN WOMEN WITH UTERINE FIBROIDS

* PHASE 3 ELARIS UF-I STUDY (M12-815) OF ELAGOLIX MET ITS PRIMARY ENDPOINT

* RESULTS DEMONSTRATED ELAGOLIX, IN COMBINATION WITH LOW-DOSE ADD-BACK THERAPY, REDUCED HEAVY MENSTRUAL BLEEDING COMPARED TO PLACEBO

* PHASE 3 ELARIS UF-I STUDY ALSO MET ALL RANKED SECONDARY ENDPOINTS (P<0.001) AT MONTH SIX Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below